Date: 2012-01-25
Type of information:
Compound:
Company: Almirall (Spain) Galapagos (Belgium)
Therapeutic area: Respiratory diseases
Type agreement: R&D
Action mechanism:
Disease: Respiratory diseases
Details: Almirall has formed a research alliance with BioFocus, an affiliate from Galapagos. The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall.
Under the terms of the collaboration, BioFocus will apply its integrated drug discovery capabilities whilst Almirall will bring in respiratory specific knowhow to the joint experimental effort.
Financial terms: The value of this collaboration could reach €7.5 million.
Latest news:
